#pinnacle-medicines

2 stories

Industry April 6, 2026 · View digest

Pinnacle Medicines Raises $89M for Oral Peptides Matching Injectable Biologics

OrbiMed-incubated startup revealed $89M in funding to develop oral peptide drugs with biologic-level efficacy. Lead program targets asthma and is on track for clinical trials.

Industry March 27, 2026 · View digest

Pinnacle Medicines Closes $89M Series B for AI-Driven Oral Peptide Pipeline

Pinnacle closed an oversubscribed $89M Series B (total $134M) to advance AI-driven oral peptide therapeutics into clinical trials, focusing on immunology and cardiometabolic diseases.